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ABSTRACT  
Background and aims: The efficacy of peginterferon/ribavirin with boceprevir or telaprevir 
was evaluated in a limited number of selected treatment-experienced cirrhotics with HCV 
genotype 1 infection.  
Methods:  511 patients with compensated cirrhosis due to HCV genotype 1 who did not 
respond to a prior course of peginterferon/ribavirin were treated for 48 weeks with either 
telaprevir or boceprevir in the framework of the French Early Access Programme (CUPIC 
cohort). The distribution was the following: 44.3% of relapsers or patients with 
breakthrough, 44.8% of partial responders and 8.0% of null responders. Virological efficacy 
(SVR12) and safety were assessed. This was an observational study which did not allow a 
head-to-head comparison between the 2 treatment regimens. 
Results: 299 and 212 patients received telaprevir and boceprevir, respectively. With 
telaprevir, the SVR12 was 74.2% in relapsers, 40.0% in partial responders and 19.4% in null 
responders. With boceprevir, the SVR12 was 53.9%, 38.3% and 0% in the same groups, 
respectively. In multivariate analysis, the SVR12 predictors were the prior treatment response, 
no lead-in phase, the HCV subtype and the baseline platelet count. Severe adverse events 
occurred in 49.9% of cases, including liver decompensation or severe infections in 10.4% and 
death in 2.2%. In multivariate analysis, the baseline albumin level and platelet count were the 
two predictors of severe side effects or death. 
Conclusions: Relatively high SVR rates can be achieved with a triple combination including 
telaprevir or boceprevir in real-life non-responders with compensated cirrhosis, at the cost of 
frequent, often severe side effects. Baseline albumin level and platelet count are useful in 
guiding treatment decisions.  
ClinicalTrials.gov number, NCT01514890. 
Key-words: chronic hepatitis C, cirrhosis, boceprevir, telaprevir. 
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Introduction 
 
Two direct-acting antiviral drugs, telaprevir (TVR) and boceprevir (BOC), both hepatitis C 
virus (HCV) non-structural 3-4A protease inhibitors (PIs), were recently approved in 
combination with pegylated interferon (Peg-IFN) and ribavirin (RBV) for the treatment of 
chronic HCV genotype 1 infection (1-4). Phase 3 trials showed significantly improved 
sustained virological response (SVR) rates compared with Peg-IFN/RBV alone in both 
treatment-naïve and treatment-experienced patients (1-4). However, the gain in efficacy was 
associated with an increased frequency of side effects, including a 20% incremental anaemia 
with both PIs, dysgeusia with BOC, and frequent skin and gastrointestinal disorders with 
TVR (1-4). Patients with cirrhosis have the greatest need for antiviral treatment given the 
higher survival rates in those who achieve an SVR compared with non-responders, as a result 
of less frequent liver failure and hepatocellular carcinoma (5-12). These patients are 
considered difficult-to-treat due to both a lower SVR rate than in non-cirrhotics and an 
increased risk of therapy. However, the administration of Peg-IFN/RBV in patients with 
compensated cirrhosis has proven to be feasible (1-4, 13-16). This patient population is 
generally under-represented in registration clinical trials, and the cirrhotics included in these 
studies are highly selected and do not reflect well the actual population of HCV-infected 
cirrhotics who are potential candidates for direct-acting antiviral–based regimens. 
The French “Autorisation Temporaire d’Utilisation” (temporary authorization for use) is an 
early access programme that gives patients access to a medicinal product before it is granted a 
marketing authorization. Patients with compensated cirrhosis who were relapsers or partial 
responders to a prior course of Peg-IFN/RBV were treated prior to approval of TVR and BOC 
within the framework of this programme, beginning in January 2011. Null responders were 
subsequently given access to these therapies when the drugs were approved. 
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The ANRS CO20 “Compassionate Use of Protease Inhibitors in viral C Cirrhosis” (CUPIC) 
study is a cohort study sponsored by the French National Agency for Research on AIDS and 
Viral Hepatitis (ANRS) that enrolled patients benefiting from the temporary authorization for 
use early access programme in selected centres. The objective of this cohort study was to 
evaluate the efficacy and safety of triple combination regimens including TVR or BOC in 
treatment-experienced cirrhotic patients in the real-life setting. This article presents the week 
60 efficacy (including SVR12) and safety results of this study. 
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Patients and methods 
 
Patients 
The ANRS CO20-CUPIC cohort is a national multicentre prospective cohort study conducted 
in 56 French centres (ClinicalTrials.gov number NCT01514890). From February 2011 to 
April 2012, patients with compensated cirrhosis (Child-Pugh class A) chronically infected 
with HCV genotype 1 who failed on a prior course of IFN with or without RBV and started 
triple combination therapy in the French Early Access Programme in the participating centres 
were included. Initially, only relapsers (or patients with a virological breakthrough) and 
partial responders were included in the Early Access Programme and recruited in the cohort. 
Null responders started to be included in the cohort study after the approval of both PIs in 
September 2011. (Supplementary materials).  
In all instances, the diagnosis of cirrhosis was confirmed by a liver biopsy or a non-invasive 
test (e.g. Fibrotest®, Fibroscan®, Fibrometer® or Hepascore®) at the investigator’s discretion, 
according to the French recommendations (17). The non-inclusion criteria were an HIV 
and/or hepatitis B virus co-infection, renal insufficiency (defined by creatinine clearance <50 
mL/min), an organ graft, and contraindication to the use of interferon. 
Written informed consent was obtained from each patient before enrolment. The protocol was 
conducted in accordance with the Declaration of Helsinki and French law for biomedical 
research and was approved by the "Ile de France IX" Ethics Committee (Créteil, France). 
 
Objectives 
The goals of the study were to evaluate the virological response defined as undetectable HCV 
RNA 12 weeks after treatment discontinuation (SVR12) based on the Food and Drug 
Administration recommendations and its safety over the full duration of treatment. 
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Treatments  
The choice between a TVR- or BOC-based regimen and the use of a lead-in were was at the 
investigator’s discretion. The patients were not randomized; thus the study did not allow for 
comparisons between the two treatment regimens. The treatment schedules and recommended 
stopping rules are described in the Supplementary materials.  
 
HCV RNA level monitoring  
HCV RNA levels were measured at baseline and at weeks 4, 8, 12, 16, 24, 36, and 48 of 
therapy, and 12 and 24 weeks after its withdrawal, with a real-time PCR-based assay, either 
COBAS AmpliPrep®/COBAS TaqMan® (Roche Molecular Systems, Pleasanton, California) 
with a lower limit of detection of 15 IU/mL, or m2000SP/m2000RT (Abbott Molecular, Des 
Plaines, Illinois), with a lower limit of detection of 12 IU/mL. Both assays have been 
validated for their accuracy in patients infected with HCV genotype 1 (18-19).  
 
Safety assessments  
The safety profile assessment is described in the Supplementary materials. Data on all adverse 
events were collected until the 60th week of follow-up. The definition of clinical and 
laboratory grade 3 or 4 adverse events, serious adverse event (SAE) and serious cutaneous 
adverse reaction (20) are described in the Supplementary materials. The factors associated 
with severe complications of cirrhosis (infection, hepatic decompensation) or death were 
explored. In addition, the factors associated with grade 3 or 4 anaemia or blood transfusion 
were also analyzed. The management of anaemia (RBV dose reductions and/or erythropoietin 
administration, authorized in France when the haemoglobin level is below 10 g/dL, and/or 
blood transfusion) was at the investigator’s discretion. Use of other hematopoietic growth 
factors for neutropenia or thrombocytopenia was also recorded. 
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Statistical analysis  
We estimated that 900 patients would be needed for the cohort to have a 3% precision in 
estimating the SVR. The efficacy and safety interim analysis was not pre-specified in the 
protocol, but decided by the Scientific Committee in February 2012 based on preliminary 
reports of safety findings. Therefore, no sample size was pre-defined. All patients who 
reached week 60 of follow-up by March 1, 2013 were included in the present analysis.  
Early virological breakthrough was defined as an undetectable HCV RNA before week 12 of 
triple therapy with detectable HCV RNA at week 12; late virological breakthrough as an 
undetectable HCV RNA after week 12 with detectable HCV RNA at week 48; relapse as an 
undetectable HCV RNA at week 48 with detectable HCV RNA at week 60 (i.e. week 12 post-
treatment); non-response as persistently detectable HCV RNA during treatment; and SVR12 
as an undetectable HCV RNA at week 60, i.e. 12 weeks after the end of therapy. Patients with 
detectable HCV RNA at week 12 had to stop therapy, according to the pre-defined stopping 
rules. Efficacy and safety analyses were performed on an intent-to-treat basis. Missing HCV 
RNA values at week 12 post-therapy were considered as treatment failures. Missing 
intermediate HCV RNA values were considered as undetectable when the preceding and 
subsequent HCV RNA levels were undetectable, and detectable otherwise. Blood parameters 
were categorized according to thresholds used to define eligibility in a recently published 
randomized trial of PI-based triple therapy (2). 
Comparisons between independent groups used the Mann-Whitney test for continuous 
variables or Fisher's exact test for categorical variables; and within-group comparisons 
were made using the Wilcoxon signed-rank test for continuous variables or McNemar's 
Chi square tests for categorical variables. Logistic regression models were used to identify 
predictors of SVR12, severe complications and grade 3/4 anaemia or blood transfusion. For 
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each tested covariate, a univariate model was estimated. Covariates with p values <.05 in 
likelihood ratio testing in univariate analysis were included in a multivariate model, and 
selection of independent covariates was based on a backward elimination procedure, retaining 
covariates with p values <.05.  
All statistical computations were performed using SAS software version 9.3 (SAS Institute 
Inc, Cary, North Carolina). 
All authors had access to the study data and had reviewed and approved the final manuscript. 
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Results 
 
Baseline demographics and disease characteristics 
Six hundred and sixty patients over 18 years of age were enrolled in 56 centres; 511 patients 
reached week 60 of follow-up and were thus included in this analysis, including 299 treated 
with TVR and 212 with BOC. The baseline demographics and disease characteristics are 
shown in Table 1. Of the 511 patients, 346 (67.7%) were men, and their mean age was 
57.0±9.7 years. The prior treatment response was a relapse or a virological breakthrough in 
226 cases (44.3%, including 17 patients with a virological breakthrough), a partial response in 
229 cases (44.8%), a null response in 41 cases (8.0%) and undetermined in the remaining 15 
cases (2.9%). At baseline, cirrhosis was compensated and classified as Child-Pugh A in 483 
patients (94.5%), and the MELD score, available in 460 patients (90.0%), was <13 in 433 of 
them (94.1%). The mean albumin level was 40.2±4.9 g/dL and the mean platelet count was 
148,000±67,000/mm3. When considering age and laboratory parameters, at least one 
exclusion criterion from the phase III studies in treatment-experienced patients (e.g. 
REALIZE and RESPOND-2) (2,4) was reported in 164 (32.1%) and 227 (44.4%) patients 
treated with TVR and BOC, respectively. The patients were infected with HCV subtype 1b in 
52.8% of cases and 62.6% of them had a baseline HCV RNA level ≥800,000 IU/mL. The 
mean treatment duration was 49.0±26.4 weeks with TVR and 46.4±26.8 weeks with BOC. 
The mean duration of PI use was 11.0±2.5 weeks with TVR and 32.4±15.1 weeks with BOC. 
 
Efficacy of triple therapy including TVR 
The intent-to-treat (ITT) efficacy analysis in the 299 patients who received TVR is shown in 
Figure 1A. The primary endpoint, ie, SVR12, was achieved in 92/124 (74.2%) patients with a 
relapse or a virological breakthrough (89/117, 76.1% and 3/7, 42.9%, respectively), 54/135 
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partial responders (40.0%), 6/31 null responders (19.4%) and 3/9 undetermined patients, 
p<0.0001. 
Among the 155 patients who achieved an SVR (all groups together), 33 (21.3%) had to 
discontinue treatment prematurely, including 8 before and 25 after week 12. The use of a 
lead-in was at the investigator’s discretion. Forty-five patients receiving TVR were treated 
with a lead-in phase: their SVR12 rate was lower than in those treated without a lead-in phase 
(15/45, 33.3% versus 140/254, 55.1%; p=0.0092). Patients treated with a lead-in were older 
(59.5 vs 56.7 years, p=0.036) and experienced more adverse events leading to premature 
treatment discontinuation: 35.6% (16/45) versus 23.8% (55/254) in the patients without lead-
in (p=0.0564).  
The SVR12 rate was significantly higher in patients infected with HCV subtype 1b than 1a: 
61.4% (102/166) versus 34.3% (35/102); p<0.0001) (Figure 1B). The difference was not 
significant between patients with more or less than 800,000 IU/mL of HCV RNA at baseline: 
48.7% (90/185) versus 57.5% (65/113); p=0.1219. The patients who achieved a rapid 
virological response (undetectable HCV RNA at treatment week 4 or at treatment week 8 in 
case of lead-in) were more likely to achieve an SVR: 63.1% (125/198) versus 29.7% 
(30/101); p<0.0001 (Figure 1C).  
Among the 144 patients who failed on triple combination therapy, 37 met the stopping rule 
criteria, including 6 (2.0% of the 299 treated patients) who experienced an early virological 
breakthrough and 31 (10.4%) who did not respond. A late virological breakthrough was 
observed after discontinuing TVR in 49 patients (16.4%), a relapse in 44 patients (14.7%) and 
14 patients (4.7%) failed due to other reasons, including loss to follow-up (7), death (4), or 
missing HCV RNA level measurements (3).  
 
Efficacy of triple therapy including BOC 
 19 
The intent-to-treat (ITT) efficacy analysis in the 212 patients who received BOC is shown in 
Figure 2A. The primary endpoint, ie, SVR12, was achieved in 55/102 (53.9%) patients with a 
relapse or a virological breakthrough (50/92, 54.3% and 5/10, 50%, respectively), 36/94 
partial responders (38.3%), 0/10 (0%) null responders, and none of the undetermined patients, 
p=0.0004. 
Among the 91 patients who achieved an SVR (all groups together), 12 (13.2%) had to 
discontinue treatment prematurely, including 2 before and 10 after week 16, i.e. lead-in plus 
12 weeks of BOC.  
The SVR rate was significantly higher in patients infected with HCV subtype 1b than 1a: 
52.9% (55/104) versus 33.3% (29/87); p=0.0084 (Figure 2B). The difference was not 
significant between patients with more or less than 800,000 IU/mL of HCV RNA at baseline: 
43.7% (59/135) versus 41.7% (30/72); p=0.8829. Higher SVR rates were observed in patients 
who exhibited a ≥1 log10 decline of HCV RNA level from baseline at treatment week 4 (end 
of lead-in) than in those who did not: 62.6% (62/99) versus 25.7% (29/113); p<0.0001 (Figure 
2C). The SVR12 was also significantly more frequent in patients with undetectable HCV 
RNA at treatment week 8 (week 4 of BOC administration): 71.6% (58/81) versus 25.2% 
(33/131); p<0.0001 (Figure 2C), and in patients who exhibited a ≥3 log10 decline of HCV 
RNA level from baseline or had undetectable HCV RNA at treatment week 8: 58.4% (87/149) 
versus 6.3% (4/63); p<0.0001.  
Among the 121 patients who failed on triple combination therapy, 62 (29.2% of the 212 
treated patients) did not respond. A virological breakthrough was observed after discontinuing 
BOC in 19 patients (9.0%), a relapse in 36 patients (17.0%) and 4 patients (1.9%) failed due 
to other reasons, including death (2), or missing HCV RNA level measurements (2).  
 
Independent predictors of SVR12 
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Patients from the TVR and BOC groups were pooled to identify factors related to the SVR12. 
The results of the univariate analysis are shown in Table 2. Four independent factors 
predicting the SVR12 were identified: the prior treatment response, including relapse or 
breakthrough (odds ratio [OR]=2.96, 95% CI: 1.97-4.44, p<0.0001) and null response 
(OR=0.28, 95% CI: 0.11-0.73, p=0.0086) versus partial response; no lead-in phase (OR=1.78, 
95% CI: 1.20-2.66, p=0.0044); a platelet count >100,000/mm3 (OR=2.15, 95% CI: 1.34-3.45, 
p=0.0015); and an HCV subtype 1b (OR=2.50, 95% CI: 1.62-3.85, p<0.0001) versus subtype 
1a. A nearly significant trend was noted with serum albumin ≥35g/L (OR=1.86, 95% CI: 
0.97- 3.56, p=0.0614).  
 
Safety 
Tables 3 and 4 show the safety profiles of the triple therapies including TVR or BOC, 
respectively. A high incidence of SAEs (n=850) was observed during the 60 weeks of follow-
up. SAEs occurred in 255 patients (49.9%), leading to early discontinuation of all drugs in 
108 (21.1%). The probability of remaining free of any serious adverse event is 
represented in the supplementary materials (Figures 1 and 2). 
Deaths occurred in 11 patients (2.2%) during the course of therapy, mainly related to severe 
infections: septicaemia (n=4), pneumonia (n=3), endocarditis (n=1). Other causes of death 
were hepatic decompensation related to variceal bleeding (n=2) and massive bleeding due to 
an aortic aneurysm (n=1). Death occurred after a median time of 20 weeks and two deaths 
occurred during the lead-in phase, i.e. without PI.  
Apart from death, severe complications, including severe infections and hepatic 
decompensation, occurred in 43 patients (8.4%). Severe infections were reported in 28 
patients (5.5%), including pneumonia (n=5), septicaemia (n=5), acute pyelonephritis (n=3), 
cutaneous infection (n=4), acute cholecystitis (n=2), infectious diarrhoea (n=2), endocarditis 
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(n=1), ascites infection (n=1), and others (n=5). These infectious complications occurred after 
a median duration of antiviral treatment of 13.9 weeks (range: 2.3 to 47.3 weeks) and during 
the lead-in phase in one patient. The peg-IFN dose was reduced or discontinued in 10 patients 
(35.7%) before the occurrence of severe infection, and in an additional 16 patients (57.1%) 
after the onset of severe infection. In addition, episodes of hepatic decompensation (without 
death or infection) were observed in 15 patients (3.1%): ascites in 14 (93.3%), 
encephalopathy in 1 (6.7%).  
Overall, 54 patients (10.6%) experienced severe complications or death. Nearly one half of 
these severe complications occurred during the first 12 or 16 (in the case of lead-in) 
weeks, independently of treatment regimens (18/38 in the TVR cohort and 8/16 in the 
BOC cohort). Age per 10-year increase (OR= 1.61, 95% CI 1.13-2.30, p=0.0087), 
baseline serum albumin <35 g/L (OR=5.43, 95% CI: 2.72-10.83, p<0.0001) and baseline 
platelet count ≤100,000/mm3 (OR=3.57, 95% CI: 1.81-7.02, p=0.0002) were independently 
associated with death or severe infection or hepatic decompensation and a non-significant 
trend was noted with baseline haemoglobin level ≤12 g/dL for women, ≤13 g/dL for men 
(OR=2.11, 95% CI: 0.96-4.63, p=0.0624). The probability of remaining free of severe 
complication or death is shown in the supplementary materials (Figures 3 and 4). 
The incidence of grade 2 anaemia (8.0 to ≤ 9.0 g/dL) was 22.9% (117/511). Grade 3-4 
anaemia (haemoglobin ≤8.0 g/dL) occurred in 11.2% of cases (57/511). Out of 174 patients 
with anaemia, 168 (96.0%) received erythropoietin, the RBV dose was reduced or 
discontinued in 133 (76.4%), and blood transfusions were administered to 78 (44.8%) (Tables 
3 and 4). Ninety-four patients (18.4%) experienced grade 3 or 4 anaemia and/or blood 
transfusion. In multivariate analysis, the predictors of severe anaemia or blood 
transfusion were as follows: age per 10-year increase (OR = 2.08, 95% CI 1.56– 2.77, p < 
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0.0001), baseline Hb ≤ 12 g/dL for females and ≤13 g/dL for males (OR = 4.30, 95% CI 
2.21–8.37, p < 0.0001) and albumin <35 g/L (OR=1.95, 95% CI: 1.02-3.73, p=0.0448). 
An increased creatinine level, defined as >80 µmol/L in women and >110 µmol/L in men, 
was observed during the treatment in the following percentages of patients: 1.04% at 
baseline, 4.6% after the first month of TVR (W4 or W8 in the case of lead-in), 6.6% at 
the end of TVR (W12 or W16 in the case of lead-in), 0% at W24 and 1% at the end of 
treatment (EOT) in the TVR cohort and 1.16% at baseline, 3.9% at W8, 5.8% at W16, 
5.3% at W24 and 2.77 at EOT in the BOC cohort. 
Risk/benefit ratio of triple therapy 
Table 5 shows the SVR12 rates and the rates of death and severe complications according to 
the two baseline predictors of severe complications and death identified in the week 16 
interim analysis, i.e. albumin level and platelet count (21).  
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Discussion  
 
The CUPIC cohort is a large cohort of treatment-experienced cirrhotic patients infected with 
HCV genotype 1 treated with BOC or TVR in combination with peg-IFN and RBV in the 
real-life setting. Because the choice of TVR or BOC was made by the treating physicians and 
the patients were not randomized, no comparison can be made between the two PIs. However, 
our results provide, for each drug regimen, an accurate reflection of what can be expected in 
terms of antiviral efficacy and safety in this particular population with a clear indication for 
antiviral therapy, which was poorly documented in phase II and phase III trials. Altogether, 
our results demonstrate a substantial benefit of adding BOC or TVR to Peg-IFN and RBV in 
these patients, compared with the 0% to 10% global SVR rates in treatment-experienced 
cirrhotic patients retreated with Peg-IFN and RBV alone in phase III trials (2, 4). 
The present study identifies baseline predictors of SVR12, including the prior treatment 
response, the absence of a lead-in phase, HCV subtype 1b, and a platelet count 
>100,000/mm3, while a nearly significant trend was observed for serum albumin ≥35 g/L. 
These parameters can now be used in this population to guide treatment decisions and 
eventually to target therapy to those patients more likely to achieve high SVR rates.  
Not surprisingly, the relapsers were the best candidates for triple therapy with BOC or TVR, 
with an SVR12 rate of 74.2% with TVR, a number in keeping with those reported in phase III 
trials. In contrast, the SVR12 rate was 53.9% with BOC, versus 83% in relapsers from the 
RESPOND-2 trial who received 48 weeks of treatment including 44 weeks of triple therapy. 
The difference could be explained by the small number of patients included in this trial 
compared with our cohort (18 versus 92 patients, respectively), and by the fact that patients 
with advanced fibrosis were pooled with cirrhotics in RESPOND-2 (22).  
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In the present study, the SVR12 rates in prior partial responders were of the order of 40%, in 
keeping with those reported in clinical trials in the same population (2, 4). In contrast, prior 
null responders rarely achieved an SVR12 (0% and 19.4% for BOC and TVR, respectively), 
suggesting that the approved triple therapy is not an appropriate therapeutic option in prior 
null responders with cirrhosis in the real-life setting. However, it is noteworthy that a small 
number of such patients were included. For BOC, data in prior null responders with cirrhosis 
are available in 3 patients in trials (23), and only 10 patients were included in our study. More 
patients (i.e. 31) were treated with TVR, and the observed SVR rate was of the same order as 
that reported in pooled non-cirrhotics and cirrhotics included in the REALIZE trial (14%) 
(16).  
In the TVR cohort, the SVR12 rate was lower in patients who received a lead-in phase. This 
result was unexpected. In the REALIZE trial, which included a large number of patients in 
both groups, no significant SVR difference was observed between the patients randomized to 
have or not to have a lead-in phase, including the same three subgroups of prior response as 
those in the present study (4). The baseline characteristics of our patients were similar in the 
two groups, except that patients with a lead-in phase were older. Moreover, we observed more 
treatment discontinuation due to adverse events in patients who received a lead-in. This result 
might have been biased by the fact that physicians decided to start with a lead-in phase in 
patients who were less likely to respond and/or more likely to develop severe complications 
of therapy. 
As already partly reported in our week 16 interim analysis (21), the safety profile over 60 
weeks of follow-up was poor for both treatment regimens, and was characterized by a large 
number of SAEs and the occurrence of severe complications, such as severe infection or 
hepatic decompensation, and death in 10.6% of patients. This may be explained in part by a 
greater mean age in our population compared with the phase III studies, and more 
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severe liver disease with a relatively high rate of portal hypertension. The management 
of anaemia was at the investigator’s discretion and involved erythropoietin prescription 
in most cases and RBV dose reduction more rarely. At the time of the study, clinicians 
were not convinced that anaemia could be managed first by RBV dose reduction without 
any impact on SVR. More recently, a prospective controlled trial has shown that RBV 
dose reduction can be the first strategy for anaemia management in treatment-naïve 
patients (24). However, it is worth noting that very few cirrhotic patients were included 
in this trial and that the SVR rate in cirrhotics was 57% in the “RBV dose reduction” 
arm versus 64% in the “erythropoietin” arm. So the validity of this strategy remains to 
be confirmed in treatment-experienced cirrhotic patients. As previously reported with 
Peg-IFN and RBV without PIs, one of the most frequent causes of severe infection was 
pneumonia (25). We did not investigate the effect of neutropenia and Peg-IFN dose 
reductions on the occurrence of these infections. However, vaccination against pneumococcus 
could be proposed before antiviral treatment. The number of patients was too small to 
evaluate the effect of this intervention. The other frequent cause of severe infection was 
septicaemia, raising the question of prophylactic antibiotic therapy during triple therapy in 
cirrhotic patients.  
In five recent studies (including a meta-analysis) evaluating the natural history of cirrhotic 
patients with characteristics comparable to those from the CUPIC cohort, the annual 
incidence of deaths and/or liver decompensation varied from 6.2 to 11%, challenging the 
indication for triple therapy in this subgroup of patients (26-30). In the present analysis, two 
baseline parameters, the serum albumin level and platelet count, were found to be 
independent predictors of severe complications or death. Interestingly, these two parameters 
were also identified as strong predictors of SVR12 in our univariate analysis, although the 
association did not reach significance for albumin in the multivariate analysis when adjusted 
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for other factors. In order to assess the risk/benefit ratio of triple therapy better in the difficult-
to-treat population of patients with compensated cirrhosis, we analyzed the SVR12 results 
with the two PIs according to baseline albumin level and platelet count. The subgroup of 
patients with both a low albumin level (<35 g/L) and a low platelet count (≤100,000/mm3) at 
baseline represented 8.3% (37/448 patients) of the population with both predictors available. 
These patients had a high risk (51.4%) of severe complications and a low SVR12 rate (27%), 
raising the question as to whether these patients, who are the most in need of therapy, should 
be treated with interferon-based triple therapy. By contrast, we identified the subgroup of 
patients with albumin ≥35 g/L and platelet count >100,000/mm3 as representing the majority 
of our population (68.3%), with a low risk of severe complications (6.2%) and a high SVR12 
rate (54.9%). This result shows that triple therapy can be used confidently in this subgroup of 
patients. The remaining patients had an incidence of severe complications between 12.2% and 
16.1% and a modest efficacy of triple therapy (29.0% to 36.5%). These patients could benefit 
from prophylaxis of treatment complications and should undergo careful monitoring while on 
therapy. Alternatively, most of them can wait for all-oral, IFN-free regimens. The lack of a 
control group does not allow us to distinguish between severe events caused by 
treatment from those caused by the cirrhosis itself. However, the rate of observed severe 
events was much higher in this particular group of patient with advanced cirrhosis, low 
platelet count and low albumin level. Moreover, severe infection is a relatively rare 
event in non-treated compensated viral cirrhosis. Therefore, it’s likely that the 
treatment contributed to these events. 
Recently, a new stopping rule has been proposed based on the on-treatment response at week 
8, as a result of post-hoc analysis of the databases of 5 clinical trials including patients with 
advanced fibrosis or cirrhosis treated with BOC. In this analysis, none of the 22 patients with 
a less than 3 log10 HCV RNA decline from baseline achieved an SVR (31). Among our 63 
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patients with a less than 3 log10 decline in HCV RNA level at week 8, only 6.3% achieved an 
SVR12. This result suggests that discontinuing triple therapy should be considered at week 12 
in these difficult-to-cure patients, especially if they tolerate treatment poorly. 
In conclusion, the CUPIC cohort study, performed in the real-life setting of patients with 
compensated cirrhosis associated with HCV genotype 1 infection, provides useful clinical 
information for the management of triple therapy in this difficult-to-treat population. It 
demonstrates the potential benefits, but also emphasizes the risks, of treating such patients 
with these therapies. In practice, the risk of developing SAEs, including severe complications 
or death, should be carefully balanced against the likelihood of a virological response and 
subsequent improvement of survival. Based on our results, three baseline parameters should 
be considered to guide treatment decisions at the individual level. They include the prior 
treatment response (triple therapy is not an optimal option for prior null responders with 
cirrhosis), the serum albumin level and the platelet count (treatment-experienced patients with 
compensated cirrhosis with a platelet count ≤100,000 /mm3 and serum albumin <35 g/L 
should not be treated with a triple combination). Relapsers and partial responders to a prior 
course of Peg-IFN/RBV and/or patients with a favourable baseline laboratory parameter 
profile can be treated, because they may benefit from therapy, but they must be carefully 
monitored. Recently, interferon-free regimens combining sofosbuvir, a nucleotide 
polymerase inhibitor + daclatasvir (NS5a inhibitor) ± RBV (32) or sofosbuvir + 
simeprevir, a second-wave protease inhibitor ± RBV (33) have yielded very promising 
results in genotype 1 naive or null responders without cirrhosis. These IFN-free 
regimens need to be evaluated in cirrhotic patients. Some patients from the CUPIC 
cohort who failed to respond to interferon-based triple therapy are currently being 
retreated with sofosbuvir + ledipasvir (NS5a inhibitor) ± ribavirin in a prospective 
randomized trial (NCT01965535).   
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Figure legends 
 
Figure 1A: Virological response with TVR according to the prior response to IFN/RBV 
therapy (ITT). 
Figure 1B: SVR12 with TVR according to the HCV subtype and prior response to IFN/RBV 
therapy (ITT) 
Figure 1C: SVR12 with TVR according to rapid virological response and the prior response 
to IFN/RBV therapy (ITT) 
 
Figure 2A: Virological response with BOC according to the prior response to IFN/RBV 
therapy (ITT) 
Figure 2B: SVR12 with BOC according to the HCV subtype and prior response to IFN/RBV 
therapy (ITT) 
Figure 2C: SVR12 with BOC according to rapid virological response and the prior response 
to IFN/RBV therapy (ITT) 
 
 30 
References 
1. Poordad F, McCone J, Jr., Bacon BR, et al. Boceprevir for untreated chronic HCV 
genotype 1 infection. N Engl J Med 2011;364:1195-1206. 
2. Bacon BR, Gordon SC, Lawitz E, et al. Boceprevir for previously treated chronic HCV 
genotype 1 infection. N Engl J Med 2011;364:1207-1217. 
3. Jacobson IM, McHutchison JG, Dusheiko G, et al. Telaprevir for previously untreated 
chronic hepatitis C virus infection. N Engl J Med 2011; 364:2405-2416. 
4. Zeuzem S, Andreone P, Pol S, et al. Telaprevir for retreatment of HCV infection. N Engl J 
Med 2011;364:2417-2428. 
5. Bruno S, Zuin M, Crosignani A, et al. Predicting mortality risk in patients with 
compensated HCV-induced cirrhosis: a long-term prospective study. Am J Gastroenterol 
2009;104:1147-1158. 
6. Dienstag JL, Ghany MG, Morgan TR, et al. A prospective study of the rate of progression 
in compensated, histologically advanced chronic hepatitis C. Hepatology 2011;54:396-405. 
7. N'Kontchou G, Paries J, Htar MT, et al. Risk factors for hepatocellular carcinoma in 
patients with alcoholic or viral C cirrhosis. Clin Gastroenterol Hepatol 2006;4:1062-1068. 
8. Sangiovanni A, Prati GM, Fasani P, et al. The natural history of compensated cirrhosis due 
to hepatitis C virus: A 17-year cohort study of 214 patients. Hepatology 2006;43:1303-1310. 
9. Bruno S, Stroffolini T, Colombo M, et al. Sustained virological response to interferon-
alpha is associated with improved outcome in HCV-related cirrhosis: a retrospective study. 
Hepatology 2007;45:579-587. 
10. Mallet V, Gilgenkrantz H, Serpaggi J, et al. Brief communication: the relationship of 
regression of cirrhosis to outcome in chronic hepatitis C. Ann Intern Med 2008;149:399-403. 
11. Morgan TR, Ghany MG, Kim HY, et al. Outcome of sustained virological responders 
with histologically advanced chronic hepatitis C. Hepatology 2010;52:833-844. 
 31 
12. van der Meer AJ, Veldt BJ, Feld JJ, et al. Association between sustained virological 
response and all-cause mortality among patients with chronic hepatitis C and advanced 
hepatic fibrosis. JAMA 2012;308:2584-2593. 
13. Bruno S, Shiffman ML, Roberts SK, et al. Efficacy and safety of peginterferon alfa-2a 
(40KD) plus ribavirin in hepatitis C patients with advanced fibrosis and cirrhosis. Hepatology 
2010;51:388-397. 
14. Marrache F, Consigny Y, Ripault MP, et al. Safety and efficacy of peginterferon plus 
ribavirin in patients with chronic hepatitis C and bridging fibrosis or cirrhosis. J Viral 
Hepatitis 2005;12:421-428. 
15. Carrion JA, Martinez-Bauer E, Crespo G, et al. Antiviral therapy increases the risk of 
bacterial infections in HCV-infected cirrhotic patients awaiting liver transplantation: A 
retrospective study. J Hepatol 2009;50:719-728. 
16. Pol S, Roberts SK, Andreone P, et al. Efficacy and safety of telaprevir-based regimens in 
cirrhotic patients with HCV genotype 1 and prior peginterferon/ribavirin treatment failure: 
subanalysis of the REALIZE phase III study. Hepatology 2011;54:374A-5A. 
17. Fontaine H, Petitprez K, Roudot-Thoraval F, et al. Guidelines for the diagnosis of 
uncomplicated cirrhosis. Gastroenterol Clin Biol 2007;31:504-509. 
18. Chevaliez S, Bouvier-Alias M, Brillet R, et al. Overestimation and underestimation of 
hepatitis C virus RNA levels in a widely used real-time polymerase chain reaction-based 
method. Hepatology 2007;46:22-31. 
19. Chevaliez S, Bouvier-Alias M, Pawlotsky JM. Performance of the Abbott real-time PCR 
assay using m2000sp and m2000rt for hepatitis C virus RNA quantification. J Clin Microbiol 
2009;47:1726-1732. 
 32 
20. Cacoub P, Bourlière M, Lubbe J, et al. Dermatological side effects of hepatitis C and its 
treatment: patient management in the era of direct-acting antivirals. J Hepatol 2012;56:455-
463. 
21. Hézode C, Fontaine H, Dorival C, et al. Triple therapy in treatment-experienced patients 
with HCV-cirrhosis in a multicentre cohort of the French Early Access Programme (ANRS 
CO20-CUPIC)-NCT01514890. J Hepatol 2013; 59: 434-441. 
22. Bruno S, Vierling JM, Esteban R, et al. Efficacy and safety of boceprevir plus 
peginterferon-ribavirin in patients with HCV G1 infection and advanced fibrosis/cirrhosis. J 
Hepatol 2013;58:479-487.  
23. Vierling JM, Davis M, Flamm S, et al. Boceprevir for chronic HCV genotype 1 infection 
in patients with prior treatment failure to peginterferon/ribavirin, including prior null 
response. J Hepatol. 2013 Dec 19. pii: S0168-8278(13)00881-7. 
doi:10.1016/j.jhep.2013.12.013. 
24. Poordad F, Lawitz E, Reddy KR, et al. Effects of ribavirin dose reduction vs 
erythropoietin for boceprevir-related anemia in patients with chronic hepatitis C virus 
genotype 1 infection-a randomized trial. Gastroenterology 2013;145:1035-1044. 
25. Roomer R, Hansen BE, Janssen HLA, et al. Risk factors for infection during treatment 
with peginterferon alfa and ribavirin for chronic hepatitis C. Hepatology 2010;52:1225-1231. 
26. Gomez EV, Rodriguez YS, Bertot LC, et al. The natural history of compensated HCV-
related cirrhosis: a prospective long-term study. J Hepatol 2013;58:434-444. 
27. Alazawi W, Cunningham M, Dearden J, Foster GR. Systematic review: outcome of 
compensated cirrhosis due to chronic hepatitis C infection. Aliment Pharmacol Ther 
2010;32:344-355. 
 33 
28. Sangiovanni A, Prati GM, Fasani P, et al. The natural history of compensated cirrhosis 
due to hepatitis C virus: A 17-year cohort study of 214 patients. Hepatology 2006;43:1303-
1310. 
29. Bruno S, Zuin M, Crosignani A, et al. Predicting mortality risk in patients with 
compensated HCV-induced cirrhosis: a long-term prospective study.  Am J Gastroenterol 
2009;104:1147-1158. 
30. Di Bisceglie AM, Shiffman ML, Everson GT, et al. Prolonged therapy of advanced 
chronic hepatitis C with low-dose peginterferon. N Engl J Med. 2008;359:2429-2441. 
31. Vierling JM, Zeuzem S, Poordad F, et al. Safety and efficacy of 
boceprevir/peginterferon/ribavirin (BOC/P/R) combination therapy for chronic HCV G1 
patients with compensated cirhrhosis: a meta-analysis of five phase 3 clinical trials. J Hepatol 
2013; 58: S576. 
32. Sulkowski MS, Gardiner DF, Rodriguez-Torres M, et al. Daclatasvir plus sofosbuvir for 
previously treated or untreated chronic HCV infection. N Engl J Med 2014;370:211-221. 
33. Jacobson IM, Ghalib RH, Rodriguez-Torres, M et al. SVR results of a once-daily regimen 
of simeprevir (TMC435) plus sofosbuvir (GS-7977) with or without ribavirin in cirrhotic and 
non-cirrhotic HCV genotype 1 treatment-naive and prior null responder patients: The 
COSMOS study Hepatology 2013; 58: 1379A-1380A  
 
 
 34 
Table 1: Baseline demographics and disease characteristics  
Characteristics TVR (n = 299) BOC (n = 212) 
Mean age (range), years 57.1 (27-83) 56.8 (34-81) 
Male gender, n (%) 202 (67.6) 144 (67.9) 
Mean body mass index (standard deviation) kg/m2 26.5 (4.2) 26.3 (4.3) 
Diabetes, n (%) 33 (11.0) 18 (8.5) 
History of ascites or variceal bleeding, n (%) 5 (1.7)  6 (2.8) 
Treatment history, n (%) 
- Prior relapse 
- Prior partial response 
- Prior null response 
- Breakthrough 
- Undetermined 
 
117 (39.1) 
135 (45.1) 
31 (10.4) 
7 (2.3) 
9 (3.0) 
 
92 (43.4) 
94 (44.3) 
10 (4.7) 
10 (4.7) 
6 (2.8) 
Mean haemoglobin level (range), g/dL 14.5 (9.0-19.7) 14.8 (9.1-18.4) 
Mean neutrophil count (range), 109/mm3 3.3 (0.8-8.5) 3.2 (0.5-8.5) 
Mean platelet count (range), /mm3 151,000  
(18,000-604,000) 
144,000  
(33,900-346,000) 
Mean alanine aminotransferase (range), IU/L 101 (0.2 – 456) 108 (5.0 - 474) 
Mean prothrombin time ratio (range), (%)  86.5 (27-100) 87.1 (23-100) 
Mean total bilirubin (range), µmol/L 15.4 (4.0-73.5) 15.1 (3.4-78.0) 
Mean serum albumin (range), g/dL 40.0 (20.7-53.2) 40.4  (27.0-50.3) 
Child-Pugh score, n (%) 
- A 
- B 
- C 
 
285 (95.3) 
6 (2.0) 
0 
 
198 (93.4) 
2 (0.9) 
0 
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- Undetermined 8 (2.7%) 12 (5.7) 
Mean MELD score* (standard deviation) 
- < 10, n (%) 
- 10 - <13, n (%) 
        -   ≥ 13, n (%) 
8.1 (2.8) 
225 (81.5) 
34 (12.3) 
17 (6.1) 
8.1 (3.0) 
153 (83.2) 
21 (11.4) 
10 (5.4) 
Upper gastrointestinal endoscopy done, n (%) 
Oesophageal varices, n (%) 
149 (49.8) 
54 (36.2) 
109 (51.4) 
41 (37.6) 
REALIZE/RESPOND-2 exclusion criteria, n (%) 101(33.8)/140(46.8) 63(29.7)/87(41.0) 
HCV genotype 1 subtype, n (%) 
- 1a 
- 1b 
- Others 
 
102 (34.1) 
166 (55.5) 
31 (10.4) 
 
87 (41.0) 
104 (49.1) 
21 (9.9) 
HCV RNA ≥ 800,000 IU/mL, n (%)** 185 (62.0) 135 (65.2) 
Creatinine clearance estimated using the 
Cockcroft-Gault formula, n (%)*** 
<60 mL/min 
60-90 mL/min 
90 mL/min 
 
 
12 (4.2) 
70 (24.4) 
204 (71.4) 
 
 
5 (2.7) 
48 (25.7) 
134 (71.6) 
* available in 276 patients for TVR and 184 patients for BOC 
** available in 298 patients for TVR and 207 patients for BOC 
*** available in 286 patients for TVR and 187 patients for BOC 
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Table 2: Baseline factors related to SVR12. Univariate and multivariate analysis 
 Univariate analysis Multivariate analysis 
 Odds 
ratio 
95% CI p-value Odds 
ratio 
95% CI p-value 
Prior treatment response 
     Partial response 
     Null response 
     Relapse or breakthrough 
No lead-in phase 
TVR 
Platelet count >100,000/mm3 
Serum albumin ≥35g/L 
No REALIZE exclusion criteria 
No RESPOND-2 exclusion criteria  
HCV subtype 
     1a 
     1b 
     Others   
 
1 
0.265 
2.874 
1.701 
1.431 
2.207 
2.718 
1.661 
1.981 
 
1 
2.713 
1.808 
 
 
0.107-0.655 
1.964-4.206 
1.198-2.414 
1.004-2.039 
1.437-3.389 
1.543-4.791 
1.139-2.422 
1.389-2.825 
 
 
1.844-3.993 
0.971-3.368 
 
 
0.0040 
<0.0001 
0.0030 
0.0472 
0.0003 
0.0005 
0.0084 
0.0002 
 
 
<0.0001 
0.0619 
 
1 
0.283 
2.956 
1.784 
 
2.148 
 
 
 
 
 
2.499 
 
 
 
0.110-0.725 
1.967-4.442 
1.198-2.657 
 
1.339-3.448 
 
 
 
 
 
1.624-3.846 
 
 
 
0.0086 
<0.0001 
0.0044 
 
0.0015 
 
 
 
 
 
<0.0001 
 
Gender, age, body weight, body mass index, diabetes, alcohol intake, cannabis smoking, haemoglobin, 
creatinine, alanine aminotransferase, HCV RNA, total bilirubin, prothrombin time, Child-Pugh score (A vs B), 
MELD score, and presence of oesophageal varices were tested in univariate analysis and were not significant 
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Table 3:  Safety profile of the triple therapy including TVR (n = 299)  
Events Week 16 Week 60 
Patients with serious adverse event, n (%)  137 (45.8)* 161 (53.8)** 
Premature treatment discontinuation (any reason), n (%) 61 (20.4) 144 (48.2) 
Premature treatment discontinuation due to SAEs, n (%) 44 (14.7) 88 (29.4) 
Discontinuation of TVR alone 3 (1.0) 3 (1.0) 
Discontinuation of RBV alone 1 (0.3) 3 (1.0) 
RBV dose reduction 22 (7.3) 44 (14.7) 
Peg-IFN dose reduction  9 (3) 17 (8.4) 
Death, n (%) 5 (1.7) 8 (2.7) 
Grade 3/4 infection, n (%) 20 (6.7) 29 (9.7) 
Grade 3/4 hepatic decompensation, n (%) 6 (2.0) 14 (4.7) 
Grade 3/4 asthenia, n (%) 16 (5.4) 19 (6.3) 
Grade 3 rash / severe cutaneous adverse reaction, n (%) 14 (4.7) / 0 16 (5.3) / 0 
Renal failure (creatinine clearance <50 mL/min), n (%)  5 (1.7) 6 (2.0) 
Anaemia, n (%) 
     Grade 2: 8.0 to ≤ 9.0 g/dL 
     Grade 3/4: < 8.0 g/dL 
Erythropoietin use 
Blood transfusion 
 
57 (19.1) 
35 (11.7) 
158 (52.8) 
47 (15.7) 
 
65 (21.7) 
38 (12.7) 
169 (56.5) 
53 (17.7) 
Neutropenia, n (%) 
     Grade 3: 500 to < 750 /mm3 
     Grade 4: < 500/mm3 
Granulocyte-stimulating agent use 
 
6 (2.0) 
3 (1.0) 
1 (0.3) 
 
8 (2.7) 
5 (1.7) 
2 (0.7) 
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Thrombocytopenia, n (%) 
     Grade 3: 20,000 to < 50,000/mm3 
     Grade 4: < 20,000/mm3 
Thrombopoietin use 
 
31 (10.4) 
10 (3.3) 
1 (0.3) 
 
35 (11.7) 
11 (3.7) 
1 (0.3) 
*356 SAEs in 137 patients, **537 SAEs in 161 patients 
 
  
 39 
Table 4:  Safety profile of the triple therapy including BOC (n = 212)  
Events Week 16  Week 60  
Patients with serious adverse event, n (%) 64 (30.2)* 94 (44.3)** 
Premature treatment discontinuation (any reason), n (%) 33 (15.6) 99 (45.7) 
Premature treatment discontinuation due to SAEs, n (%) 10 (4.7) 36 (17) 
Discontinuation of BOC alone 0 (0) 2 (0.9) 
Discontinuation of RBV alone 0 (0) 3 (1.4) 
RBV dose reduction 11 (5.2) 27 (12.7) 
Peg-IFN dose reduction  3 (1.4) 14 (6.6) 
Death, n (%) 1 (0.5) 3 (1.4) 
Grade 3/4 infection, n (%) 4 (1.9) 8 (3.8) 
Grade 3/4 hepatic decompensation, n (%) 6 (2.8) 9 (4.2) 
Grade 3/4 asthenia, n (%) 10 (4.7) 13 (6.1) 
Grade 3 rash / severe cutaneous adverse reaction, n (%) 0 / 0 2 / 0 (0.9) 
Renal failure (creatinine clearance <50 mL/min), n (%)  0 1 (0.5) 
Anaemia, n (%) 
     Grade 2: 8·0 to ≤ 9.0 g/dL 
     Grade 3/4: < 8.0 g/dL 
Erythropoietin use 
Blood transfusion 
 
50 (23.6) 
10 (4.7) 
93 (43.9) 
14 (6.6) 
 
52 (24.5) 
19 (9.0) 
119 (56.1) 
25 (11.8) 
Neutropenia, n (%) 
     Grade 3: 500 to < 750 /mm3 
     Grade 4: < 500/mm3 
Granulocyte-stimulating agent use 
 
3 (1.4) 
6 (2.8) 
4 (1.9) 
 
6 (2.8) 
7 (3.3) 
6 (2.8) 
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Thrombocytopenia, n (%) 
     Grade 3: 20,000 to < 50,000/mm3 
     Grade 4: < 20,000/mm3 
Thrombopoietin use 
 
10 (4.7) 
3 (1.4 ) 
1 (0.5) 
 
15 (7.1) 
5 (2.4) 
2 (0.9) 
*153 SAEs in 64 patients, **313 SAEs in 94 patients
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Table 5: Risk of death or severe complications and SVR12 according to serum albumin 
level and platelet count* 
 
Factors Platelet count  
>100,000 /mm3 
Platelet count  
≤100,000 /mm3 
Serum albumin 35 g/L 
Patients, n (%) 
Patients with severe complications or 
death, n (%) 
Patients with SVR12, n (%) 
 
306 (68.3%) 
 
19 (6.2%) 
168 (54.9%) 
 
74 (16.5%) 
 
9 (12.2%) 
27 (36.5%) 
Serum albumin <35 g/L 
Patients, n (%) 
Patients with severe complications or 
death, n (%) 
Patients with SVR12, n (%) 
 
31 (6.9%) 
 
5 (16.1%) 
9 (29.0%) 
 
37 (8.3%) 
 
19 (51.4%) 
10 (27.0%) 
*Baseline albumin and platelet count were available in 448 patients (missing data in 63 
patients for albumin and/or platelet count). 10 deaths were reported and analyzed in these 448 
patients. 
 
 
 
